Marker Therapeutics Files 8-K on Financials
Ticker: MRKR · Form: 8-K · Filed: Aug 14, 2024 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 8-K |
| Filed Date | Aug 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, 8-K, company-update
TL;DR
Marker Therapeutics dropped an 8-K on financials, check it out.
AI Summary
Marker Therapeutics, Inc. filed an 8-K on August 14, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. The company, formerly known as TAPIMMUNE INC. and GENEMAX CORP, is incorporated in Delaware and headquartered in Houston, Texas.
Why It Matters
This filing provides crucial updates on Marker Therapeutics' financial health and operational status, which is important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Marker Therapeutics, Inc. (company) — Registrant
- TAPIMMUNE INC. (company) — Former Company Name
- GENEMAX CORP (company) — Former Company Name
- August 14, 2024 (date) — Filing Date
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K report filed with the SEC?
The report was filed on August 14, 2024.
What are the previous names of Marker Therapeutics, Inc.?
Marker Therapeutics, Inc. was formerly known as TAPIMMUNE INC. and GENEMAX CORP.
In which state is Marker Therapeutics, Inc. incorporated?
The company is incorporated in Delaware.
What is the business address of Marker Therapeutics, Inc.?
The business address is 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, Texas 77021.
Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-08-14 16:47:43
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
Filing Documents
- tm2421372d1_8k.htm (8-K) — 24KB
- tm2421372d1_ex99-1.htm (EX-99.1) — 111KB
- tm2421372d1_ex99-1img001.jpg (GRAPHIC) — 6KB
- 0001104659-24-089704.txt ( ) — 327KB
- mrkr-20240814.xsd (EX-101.SCH) — 3KB
- mrkr-20240814_lab.xml (EX-101.LAB) — 33KB
- mrkr-20240814_pre.xml (EX-101.PRE) — 22KB
- tm2421372d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On August 14, 2024, Marker Therapeutics, Inc. (the " Company ") reported financial results for the quarter ended June 30, 2024 and other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference. The information in this Item 2.02 of this Current Report on 8-K (including Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated August 14, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Marker Therapeutics, Inc. Dated: August 14, 2024 By: /s/ Juan Vera Juan Vera President and Chief Executive Officer